F
Fosun Antekin
Developer of mRNA and conjugate vaccine technologies.
About Fosun Antekin
Fosun Adgenvax Biopharmaceutical is a controlling subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd., focused on the research, development, and commercialization of vaccines. The company is a key part of Fosun Pharma's vaccine business segment and has been preparing for a potential spin-off listing on the main board of the Hong Kong Stock Exchange. The company's pipeline includes advanced vaccine technologies. Notably, Fosun Adgenvax has been involved in the strategic collaboration between its parent company, Fosun Pharma, and BioNTech, which began in March 2020 to develop and commercialize a COVID-19 mRNA vaccine. This partnership led to clinical trials and subsequent distribution of the mRNA vaccine in Hong Kong SAR, Macau SAR, and the Taiwan region. In addition to its work with mRNA technology, Fosun Adgenvax is independently developing other vaccines, such as a 13-valent pneumococcal conjugate vaccine for the prevention of pneumococcal infections. Fosun Adgenvax is positioned to leverage its parent company's extensive global network and resources. Fosun Pharma was founded in 1994 and has grown into a global pharmaceutical and healthcare group with operations in research, manufacturing, medical devices, and healthcare services. Recent activities for Fosun Adgenvax include securing a capital increase of approximately RMB 968 million to expand its R&D pipeline, enhance production capabilities, and support the commercialization of its products. The company has also obtained a Drug Manufacturing Licence and a Drug Operation Licence, crucial steps for the commercial sale of its vaccine products.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2012
- Headquarters
- Chengdu, China
- Open positions
- None listed
- Dealroom signal
- 20.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Drug Development, Vaccines, Became $1B as Subsidiary, mRNA Medicines
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Jun 2026 | $133M | $1.1B | Undisclosed | ↗ |
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Fosun Antekin in the Chengdu ecosystem
The Fosun Antekin office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Fosun Antekin on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Fosun Antekin’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








